Skip to main content

Table 2 Distribution of clinical variables, sarcopenia phenotypes, and fracture risk in women with breast cancer

From: Muscle strength is associated with fracture risk obtained by fracture risk assessment tool (FRAX) in women with breast cancer

Variables (n = 62)

n (%)

Clinical staging

  0

3 (4.8)

  I

20 (32.3)

  II

28 (45.2)

  III

11 (17.7)

Histological subtype

  Invasive breast carcinoma

40 (64.5)

  Invasive ductal carcinoma

6 (9.7)

  In situ ductal carcinoma

3 (4.8)

  Special subtypes

13 (21.0)

Diagnosis time (months)

  < 6

51 (82.3)

  6 – 12

11 (17.7)

Type of treatment

  No previous treatment

29 (46.8)

  Neoadjuvant

10 (16.1)

  Surgical

9 (14.5)

  Adjuvant

14 (22.6)

Menopausal status

  Pre-menopause

11 (17.7)

  Post-menopause

51 (82.3)

Menopause time (years)1

  ≤ 15

27 (52.9)

  > 15

24 (47.1)

  1. 1n = 51